Filing Details
- Accession Number:
- 0001237899-19-000037
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-13 17:43:52
- Reporting Period:
- 2019-12-11
- Accepted Time:
- 2019-12-13 17:43:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 872589 | Regeneron Pharmaceuticals Inc. | REGN | Pharmaceutical Preparations (2834) | 133444607 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1013064 | Roy P Vagelos | 777 Old Saw Mill River Road Tarrytown NY 10591 | Chairman Of The Board | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-12 | 107,655 | $21.25 | 412,140 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-12 | 55,813 | $377.16 | 356,327 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2019-12-13 | 632 | $373.26 | 355,695 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-13 | 6,873 | $374.79 | 348,822 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-13 | 21,910 | $375.55 | 326,912 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-13 | 13,060 | $376.36 | 313,852 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-13 | 5,732 | $377.47 | 308,120 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-13 | 3,602 | $378.38 | 304,518 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-13 | 33 | $379.14 | 304,485 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2019-12-12 | 107,655 | $0.00 | 107,655 | $21.25 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Acquisiton | 2019-12-11 | 29,177 | $0.00 | 29,177 | $372.46 |
| Common Stock | Performance Stock Units | Acquisiton | 2019-12-11 | 9,086 | $0.00 | 9,086 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2019-12-18 | No | 4 | M | Direct | |
| 29,177 | 2029-12-11 | No | 4 | A | Direct | |
| 9,086 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,326 | Indirect | By 401(k) Plan |
| Common Stock | 144,897 | Indirect | by CLAT |
| Common Stock | 83,652 | Indirect | by Spouse as Trustee |
| Common Stock | 1,203 | Indirect | by trust for grandch |
Footnotes
- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 632 shares of Company stock on December 13, 2019 at prices ranging from $373.21 to $373.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- Represents volume-weighted average price of sales of 6,873 shares of Company stock on December 13, 2019 at prices ranging from $374.22 to $374.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- Represents volume-weighted average price of sales of 21,910 shares of Company stock on December 13, 2019 at prices ranging from $375.02 to $375.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- Represents volume-weighted average price of sales of 13,060 shares of Company stock on December 13, 2019 at prices ranging from $376.00 to $376.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- Represents volume-weighted average price of sales of 5,732 shares of Company stock on December 13, 2019 at prices ranging from $377.01 to $377.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- Represents volume-weighted average price of sales of 3,602 shares of Company stock on December 13, 2019 at prices ranging from $378.07 to $378.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- Represents volume-weighted average price of sales of 33 shares of Company stock on December 13, 2019 at prices ranging from $379.06 to $379.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- The stock option award vests in four equal annual installments, commencing one year after the date of grant.
- Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires.
Billionaire Hedge Funds
